MPPED2-AS1: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Target Name: MPPED2-AS1

NCBI ID: G105376609

MPPED2-AS1

Other Name(s): MPPED2 antisense RNA 1, transcript variant X1 | MPPED2 antisense RNA 1

MPPED2-AS1: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Abstract:

Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow, where blood cells are produced. The disease is characterized by the uncontrolled production of white blood cells, particularly leukemia cells. MPPED2-AS1, a non-coding RNA molecule known as an antisense RNA 1 in humans, has been identified as a potential drug target and biomarker for CML. This article will discuss the characteristics of MPPED2-AS1, its potential implications as a drug target and biomarker, and current research efforts to investigate its role in the treatment of CML.

Introduction:

CML is a type of cancer that affects the bone marrow, where blood cells are produced. The disease is characterized by the uncontrolled production of white blood cells, particularly leukemia cells. According to the World Health Organization (WHO), CML is the most common type of leukemia in adults, affecting approximately 218,000 people globally each year. The treatment of CML is currently limited to chemotherapy, radiation therapy, and bone marrow transplantation, which are often associated with significant side effects. Therefore, there is a need for new treatments and biomarkers to improve the treatment outcomes for CML patients.

MPPED2-AS1: A Non-Code RNA Molecule with Potential as a Drug Target and Biomarker

MPPED2-AS1, a non-coding RNA molecule identified by researchers, has been shown to play a critical role in the regulation of hematopoietic stem cell (HSC) proliferation and differentiation. The molecule is known as antisense RNA 1 in humans and has been shown to suppress the activity of the oncogene MPPED2, which is responsible for the production of leukemia-promoting proteins.

Studies have demonstrated that MPPED2-AS1 has the potential to be a drug target for CML. By inhibiting the activity of MPPED2, MPPED2-AS1 may be able to reduce the production of leukemia cells and improve the treatment outcomes for CML patients. Additionally, MPPED2-AS1 has been shown to be expressed in different types of leukemia, including blastic plasmacytoid dendritic cell neoplasm (BPdC), a type of leukemia that is characterized by the production of large B-cell lymphocytes. Therefore, MPPED2-AS1 may also be a potential biomarker for the treatment of BPdC.

Potential Biomarker and Drug Target

MPPED2-AS1 has been shown to play a critical role in the regulation of HSC proliferation and differentiation, which may have implications for the treatment of CML. By inhibiting the activity of MPPED2, MPPED2-AS1 may be able to reduce the production of leukemia cells and improve the treatment outcomes for CML patients. Additionally, the regulation of HSC proliferation and differentiation by MPPED2-AS1 may be a potential biomarker for the diagnosis and prognosis of CML.

Current Research Efforts

Several studies have investigated the potential role of MPPED2-AS1 as a drug target and biomarker for CML. For example, researchers have shown that inhibiting the activity of MPPED2 using small interfering RNA (siRNA) can reduce the production of leukemia cells in CML cell cultures. Additionally, researchers have used RNA sequencing (RNA-seq) to identify differentially expressed genes in CML samples and show that MPPED2-AS1 is involved in the regulation of HSC proliferation and differentiation.

Conclusion:

MPPED2-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for CML. Its role in the regulation of

Protein Name: MPPED2 Antisense RNA 1

The "MPPED2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPPED2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets